Peptron Inc

Peptron Inc has a current liquidity position that is medium risk, with a negative free cash flow of -14,105,420,950 KRW and a negative operating cash flow of -20,586,335,440 KRW. The company's cash and equivalents amount to 4,377,757,820 KRW, which is insufficient to cover its long-term debt of 29,555,360,280 KRW, resulting in a net cash position that is negative after subtracting total debt. The company's profitability is negative, with a return on equity of -9.73% and a return on assets of -7.72%. These figures are significantly below the industry median for biotechnology and medical research firms, indicating a weak performance in generating returns for shareholders and asset utilization. Peptron Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks and could limit its ability to grow through new markets. The company's growth trajectory is uncertain, with a net loss of 13,823,782,610 KRW in the latest reporting period. Analysts have recorded a last actual revenue of 3,120,700,000 KRW, which is lower than the company's reported revenue of 5,634,817,680 KRW, suggesting potential discrepancies or a recent decline in performance. Peptron Inc faces a medium liquidity risk, as indicated by its negative operating and free cash flows. The company's dilution risk is low, with no significant dilution sources identified in the available data. However, the company's negative net income and operating income suggest a need for external financing, which could increase dilution risk in the future. Recent events include the company's financial performance, as disclosed in its latest financial statements, which show a significant net loss and negative cash flows. No recent filings or transcripts have been provided that detail specific strategic or operational changes.